- 20 January 2023
- journal article
- letter
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 41 (3) , 704-706
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Predicting the Risk of Progression in Patients With Kidney Cancer: Aiming at the Optimal Tool in the Optimal SettingJournal of Clinical Oncology, 2023
- External Validation of the 2003 Leibovich Prognostic Score in Patients Randomly Assigned to SORCE, an International Phase III Trial of Adjuvant Sorafenib in Renal Cell CancerJournal of Clinical Oncology, 2022
- Head-to-head comparison of all the prognostic models recommended by the European Association of Urology Guidelines to predict oncologic outcomes in patients with renal cell carcinomaUrologic Oncology: Seminars and Original Investigations, 2022
- RAMPART: A phase III multi-arm multi-stage trial of adjuvant checkpoint inhibitors in patients with resected primary renal cell carcinoma (RCC) at high or intermediate risk of relapseContemporary Clinical Trials, 2021
- Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell CarcinomaNew England Journal of Medicine, 2021
- Leibovich score is the optimal clinico-pathological system associated with recurrence of non-metastatic clear cell renal cell carcinomaUrologic Oncology: Seminars and Original Investigations, 2021
- Adjuvant Sorafenib for Renal Cell Carcinoma at Intermediate or High Risk of Relapse: Results From the SORCE Randomized Phase III Intergroup TrialJournal of Clinical Oncology, 2020